Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Phase 1 Recruiting
24 enrolled
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Phase 2 Recruiting
121 enrolled
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1/2 Recruiting
15 enrolled
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 Recruiting
40 enrolled
TRIBE-C
Phase 3 Recruiting
528 enrolled
PANCREAS
Phase 2 Recruiting
84 enrolled
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Phase 1 Recruiting
30 enrolled
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Phase 3 Recruiting
382 enrolled
FOBEAR
Phase 3 Recruiting
582 enrolled
RePaIr-HN
Phase 3 Recruiting
214 enrolled
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Phase 2 Recruiting
36 enrolled
REDUCE
Phase 2 Recruiting
86 enrolled
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Phase 2 Recruiting
36 enrolled
SMART TNT
Phase 1 Recruiting
25 enrolled
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/2 Recruiting
35 enrolled
CAPRI-3 GOIM
Phase 3 Recruiting
480 enrolled
Adaptive Radiation in Anal Cancer
Phase NA Recruiting
20 enrolled
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Phase 3 Recruiting
550 enrolled
LAP100
Phase 3 Recruiting
356 enrolled
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Phase 3 Recruiting
486 enrolled
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Recruiting
25 enrolled
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2 Recruiting
49 enrolled
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Phase 2 Recruiting
200 enrolled
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 Recruiting
300 enrolled
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Phase 1/2 Recruiting
27 enrolled
PANC
Phase 2 Recruiting
125 enrolled
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2 Recruiting
100 enrolled
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Phase 1 Recruiting
15 enrolled
CEIL
Phase 2 Recruiting
198 enrolled
AIO-KRK-0418
Phase 3 Recruiting
507 enrolled
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Phase 1 Recruiting
49 enrolled
AtezoTRIBE2
Phase 3 Recruiting
238 enrolled
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2 Recruiting
20 enrolled
GRACIE
Phase 2 Recruiting
88 enrolled
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
Phase 2 Recruiting
24 enrolled
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Phase 4 Recruiting
100 enrolled
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Phase 1 Recruiting
25 enrolled
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Phase 2 Recruiting
60 enrolled
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Phase 1 Recruiting
24 enrolled
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Phase 2 Recruiting
100 enrolled
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Phase 1 Recruiting
128 enrolled
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Phase 1/2 Recruiting
40 enrolled
I-FLOAT
Phase 1 Recruiting
54 enrolled
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2 Recruiting
20 enrolled
BIG
Phase 2 Recruiting
120 enrolled
Establishing Best Treatment Strategy for T4 Esophageal Cancer
Phase 1/2 Recruiting
22 enrolled
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
Phase 2 Recruiting
44 enrolled
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
Phase 2 Recruiting
29 enrolled
The Sagittarius Trial
Phase 3 Recruiting
700 enrolled
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
26 enrolled